Investors

H1 2026 Results

Results for H1 2026 were published on July 30, 2026.
The recording of Ipsen’s H1 2026 Results Call is now available on demand.
Watch the recording

The latest highlights from Investor Relations

Find out what’s been happening at Ipsen Investor Relations lately – including financial results, announcements, IR events, and more.

12 February 2026
FY 2025 Results

31 July 2025
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance

16 April 2025
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

10 April 2025
Q1 2025 sales update

13 March 2025
Ipsen announces assigned Investment Grade ratings from S&P Global Ratings and Moody’s

13 February 2025
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and…

12 January 2025
J.P. Morgan Healthcare Conference

Investing for growth

We see everyone within the Ipsen investor community as a valued stakeholder who helps drive our overall success. Dedicated to transparency and ethical decision-making, we aim to provide investors with the resources they need to understand our company and how we plan to reach our ambitious targets.

Underpinned by a robust balance sheet and strong cash generation, we have the ambition to replenish our pipeline. With a successful strategy, we’re proud to be backed by an investor community that recognizes our positive progress.
Aymeric Le Chatelier
EVP, Chief Financial Officer

Ipsen's latest investor presentation

Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
Please find below Ipsen’s latest investor presentation, reflecting our most recent messaging and key updates on strategy, performance and pipeline.
Learn more

Strong results backed by innovation

With total sales growth of over 9%*, we delivered strong results in 2024, and we’ve had a strong start to 2025. We are on track to build further momentum in our transformation, and to achieve our objectives for the year.
*At constant exchange rate.

Download Ipsen's Annual Report

Pipeline

Our robust development pipeline, backed by our expertise and external-innovation strategy, supports patients’ health outcomes across our three therapeutic areas of Oncology, Rare Disease and Neuroscience.
Learn more

Shareholder information

We aim to transparently communicate to our investor community our analyst coverage, ADR program and shareholding structure.
Learn more

Regulated information

Information on voting rights updates, combined shareholders’ meeting and our share buyback program. View the publications and press releases related to regulated information.
Learn more

Five-year stock information

Share price and stock information, benchmark, orders, transactions: discover the data related to Ipsen’s shares.
Learn more